Published in J Neurochem on January 01, 1984
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med (1990) 3.05
Increased blood pressure reactivity to dietary salt in patients with the metabolic syndrome. J Hum Hypertens (2007) 1.63
Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer (1992) 1.31
A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA (1986) 1.09
Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J Pharmacol Exp Ther (1988) 1.07
Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. J Hum Hypertens (2005) 1.02
The role of calcium channel blockers in the treatment of hypertension. Am Heart J (1986) 1.01
Clinical pharmacology of carvedilol in normal volunteers. Clin Pharmacol Ther (1987) 0.98
Operational characteristics of the inhibitory feedback mechanism for regulation of dopamine release via presynaptic receptors. J Pharmacol Exp Ther (1982) 0.93
Sustained high release at rapid stimulation rates and reduced functional autoreceptors characterize prefrontal cortex dopamine terminals. J Pharmacol Exp Ther (1988) 0.92
Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol (1993) 0.91
Dopamine autoreceptors modulate dopamine release from the prefrontal cortex. J Neurochem (1986) 0.88
Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol (1988) 0.86
Pharmacologic characterization and functional role of muscarinic autoreceptors in the rabbit striatum. J Pharmacol Exp Ther (1987) 0.85
Frequency-dependent muscarinic receptor modulation of acetylcholine and dopamine release from rabbit striatum. J Pharmacol Exp Ther (1984) 0.85
Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther (1999) 0.84
Salt sensitivity is associated with insulin resistance in essential hypertension. Am J Hypertens (1998) 0.84
Urinary albumin excretion in lean, overweight and obese glucose tolerant individuals: its relationship with dyslipidaemia, hyperinsulinaemia and blood pressure. J Hum Hypertens (2001) 0.84
Expression of inducible nitric oxide synthase in primary culture of rat bladder smooth muscle cells by plasma from cyclophosphamide-treated rats. Eur J Pharmacol (2001) 0.83
Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics. J Hum Hypertens (2007) 0.83
Nitric oxide and salt sensitivity. Am J Hypertens (2000) 0.82
Release of norepinephrine and dopamine-beta-hydroxylase by nerve stimulation. V. Enhanced release associated with a granular effect of a benzoquinolizine derivative with reserpine-like properties. J Pharmacol Exp Ther (1975) 0.82
Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci (1986) 0.81
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer (1996) 0.81
Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. J Pharmacol Exp Ther (1984) 0.81
NAD(P)H oxidase p22phox gene C242T polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. J Hum Hypertens (2006) 0.81
Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab (2000) 0.81
Verapamil and propranolol in essential hypertension. Clin Pharmacol Ther (1984) 0.80
Urinary excretion of nitric oxide metabolites in runners, sedentary individuals and patients with coronary artery disease: effects of 42 km marathon, 15 km race and a cardiac rehabilitation program. J Cardiovasc Risk (1999) 0.80
Frequency-dependent release of acetylcholine and dopamine from rabbit striatum: its modulation by dopaminergic receptors. J Neurochem (1983) 0.80
Microalbuminuria: do we need a new threshold? J Hum Hypertens (2008) 0.80
Do humoral factors mediate cancer chemotherapy-induced emesis? Drug Metab Rev (1989) 0.80
Nitric oxide synthases and cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.80
Rate and duration of stimulation determine presynaptic effects of haloperidol on dopaminergic neurons. J Neurochem (1982) 0.79
Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer (1995) 0.79
Liquid chromatographic assay and disposition of carvedilol in healthy volunteers. J Pharm Sci (1986) 0.79
Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores. J Pharmacol Exp Ther (1986) 0.79
Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. II. Release in the presence of vesicular transmitter stores. J Pharmacol Exp Ther (1986) 0.79
Metabolism and efflux of [3H]dopamine in rat neostriatum: presynaptic origin of 3,4-[3H]dihydroxyphenylacetic acid. J Pharmacol Exp Ther (1979) 0.79
Comparative effects of verapamil and volume overload on atrial natriuretic factors and the renin-angiotensin aldosterone-vasopressin system. J Clin Pharmacol (1992) 0.78
Insulin resistance and upper-normal glucose levels in hypertension: a review. J Hum Hypertens (2002) 0.78
Effects of inhibition of serotonin synthesis on 5-hydroxyindoleacetic acid excretion, in healthy subjects. J Clin Pharmacol (1994) 0.78
Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. J Pharmacol Exp Ther (1990) 0.78
Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther (1987) 0.78
Monoamine release by compound 48/80 from nonmast cell compartments in mouse brain slices. J Pharmacol Exp Ther (1988) 0.78
Clustering of silent cardiovascular risk factors in apparently healthy Hispanics. J Hum Hypertens (2002) 0.78
Dopamine-beta-hydroxylase activity in human cerebrospinal fluid. J Neurochem (1976) 0.78
Ventral and dorsal striatal cholinergic neurons have different sensitivities to kainic acid. Neurochem Int (1997) 0.78
Differential effects of kainic acid on dopamine and serotonin metabolism in ventral and dorsal striatal regions. Brain Res (1997) 0.78
Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients. Br J Cancer (1995) 0.78
Differential blood pressure effects of oral glucose and intravenous L-arginine in healthy lean normotensive and obese hypertensive subjects. J Hum Hypertens (2002) 0.77
Clonidine reduces elevated cerebrospinal fluid catecholamine levels in patients with essential hypertension. Life Sci (1984) 0.77
Evidence for autoreceptor modulation of endogenous dopamine release from rabbit caudate nucleus in vitro. J Pharmacol Exp Ther (1985) 0.77
Rapid desensitization of dopamine release induced by neurotensin and neurotensin fragments. J Pharmacol Exp Ther (1990) 0.77
Thermodynamic analyses of the binding of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with [3H]GBR 12783 or [3H]mazindol. J Pharmacol Exp Ther (1990) 0.77
Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther (1996) 0.77
Nitric oxide and NK(1)-tachykinin receptors in cyclophosphamide-induced cystitis, in rats. J Pharmacol Exp Ther (2000) 0.77
Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release. J Pharmacol Exp Ther (1986) 0.77
Relations between fasting serum insulin, glucose, and dihydroepiandrosterone-sulfate concentrations in obese patients with hypertension: short-term effects of antihypertensive drugs. J Cardiovasc Pharmacol (1997) 0.77
Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum. J Pharmacol Exp Ther (1989) 0.77
Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. Drugs (1992) 0.76
Is the release of dopamine from medial prefrontal cortex modulated by presynaptic receptors? Comparison with nigrostriatal and mesolimbic terminals. Ann N Y Acad Sci (1990) 0.76
Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat. Naunyn Schmiedebergs Arch Pharmacol (2000) 0.76
Insulin and blood pressure responses to changes in salt intake. J Hum Hypertens (2000) 0.76
Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. J Cardiovasc Pharmacol (1989) 0.76
Effects of low extracellular chloride on dopamine release and the dopamine transporter. J Pharmacol Exp Ther (1989) 0.76
Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine. J Pharmacol Exp Ther (1989) 0.76
Effects of amiloride and 5-(N,N-hexamethylene)amiloride on dopaminergic and cholinergic neurotransmission. J Pharmacol Exp Ther (1988) 0.76
Level of punishment determines anticonflict activity of ondansetron in pigeons: comparison with buspirone and diazepam. Pharmacol Biochem Behav (1998) 0.75
Effects of propranolol, clonidine and hydrochlorothiazide treatment and abrupt discontinuation on central and peripheral noradrenergic activity in essential hypertension. Life Sci (1986) 0.75
Effects of short- and long-term exercise on urinary cGMP excretion in healthy subjects and in patients with coronary artery disease. J Cardiovasc Pharmacol (2000) 0.75
Effects of chemical sympathectomy on the increases in plasma catecholamines and dopamine-beta-hydroxylase induced by forced immobilization and insulin-induced hypoglycemia: origin and fate of plasma dopamine-beta-hydroxylase. J Pharmacol Exp Ther (1982) 0.75
Beta blockade by oral propranolol and labetalol. Clin Pharmacol Ther (1985) 0.75
Ionic mechanism of dopaminergic and muscarinic auto- and heteroreceptor activation in superfused striatal slices: role of extracellular chloride. J Pharmacol Exp Ther (1987) 0.75
Changes in the sensitivity to apomorphine of dopamine receptors modulating dopamine and acetylcholine release after chronic treatment with bromocriptine or haloperidol. J Pharmacol Exp Ther (1983) 0.75
Carbachol-phorbol ester interactions at muscarinic receptors modulating dopamine release from rabbit striatal slices. Neurosci Lett (1991) 0.75
Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats. Clin Pharmacol Ther (1984) 0.75
Presynaptic effects of 2-aminotetralins on striatal dopaminergic neurons. J Pharmacol Exp Ther (1980) 0.75
Presynaptic effects of tetrahydropapaveroline on striatal dopaminergic neurons. J Pharmacol Exp Ther (1982) 0.75
Naloxone does not antagonize the antihypertensive effect of clonidine in essential hypertension. Clin Pharmacol Ther (1983) 0.75
Frequency-dependent effects of neuronal uptake inhibitors on the autoreceptor-mediated modulation of dopamine and acetylcholine release from the rabbit striatum. J Pharmacol Exp Ther (1983) 0.75
Cerebrospinal fluid and plasma dopamine-beta-hydroxylase activity in human hypertension. Hypertension (1982) 0.75
Differential effects of muscarinic receptor agonists and phorbol ester on muscarinic and D2-dopamine release-modulatory receptors. J Pharmacol Exp Ther (1996) 0.75
Prazosin and propranolol in preoperative management of pheochromocytoma. Clin Pharmacol Ther (1982) 0.75
Differential effects of phorbol ester on prefrontal cortex and striatal dopamine terminals: dependence on rate and duration of stimulation. J Pharmacol Exp Ther (1989) 0.75
Comparative dopamine-acetylcholine interactions in the ventral and dorsal striatum of rabbit and rat brain. Brain Res (1996) 0.75
Effects of papaverine on the release and metabolism of dopamine in rat striatum. J Pharmacol Exp Ther (1979) 0.75